Health
FDA approves first treatment for a rare genetic disorder – News-Medical.Net
Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder.
Reviewed by Emily Henderson, B.Sc.Nov 23 2020
Today, the U.S. Food and Drug Administration approved Oxlumo (lumasiran) as the first treatment for primary hyperoxaluria type 1 (PH1), a rare genetic disorder. This approval is a cumulation of the work of experts and community members coordinated by the Oxalosis & Hyperoxaluria Foundation and the Kidney Health Initiative.
The approval of Oxlumo represents a great triumph of community involvement to address a rare disease. It is a result of input…
-
Noosa News17 hours agoBlute’s Bar Is Picking Up Where The Bearded Lady Left Off, Adding Live Music to Its Late-Night Karaoke Sing-Alongs
-
General21 hours agoTrump meeting cancellation ‘always a chance’: treasurer
-
General15 hours agoIs Australia derivative? | The Spectator Australia
-
Noosa News17 hours agoThe 40 stitches that failed to stop Dolphins hooker Jeremy Marshall-King